S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The #1 Crypto for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The only accurate crypto trading system I know … (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The #1 Crypto for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The only accurate crypto trading system I know … (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The #1 Crypto for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The only accurate crypto trading system I know … (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The #1 Crypto for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The only accurate crypto trading system I know … (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
Free Trial
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)
Free IMPL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.04
▼
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media
IMPL stock logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

IMPL Stock News Headlines

March 13, 2024 | finance.yahoo.com
Impel Pharmaceuticals Inc. (IMPLQ)
December 20, 2023 | markets.businessinsider.com
Impel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 Protection
April 18, 2024 | Banyan Hill Publishing (Ad)
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
December 20, 2023 | finance.yahoo.com
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
November 6, 2023 | bizjournals.com
Adrian Adams steps down as CEO of Seattle's Impel Pharmaceuticals
October 9, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)
October 5, 2023 | finance.yahoo.com
Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
September 14, 2023 | markets.businessinsider.com
Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading
April 18, 2024 | Banyan Hill Publishing (Ad)
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
September 8, 2023 | msn.com
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
August 22, 2023 | markets.businessinsider.com
JonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)
August 16, 2023 | marketwatch.com
Impel Pharma Shares Tumble 46% After Breaching Terms of Credit Agreement
August 16, 2023 | msn.com
Impel Pharma (NASDAQ:IMPL) Plummets on Viability Concerns
August 16, 2023 | investorplace.com
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
July 5, 2023 | theglobeandmail.com
Biotech Catches Major Premarket Bid
July 3, 2023 | finance.yahoo.com
84P.SG - Impel Pharmaceuticals Inc
June 21, 2023 | benzinga.com
Director at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 Shares
June 21, 2023 | benzinga.com
Impel Pharmaceuticals Board Member Awarded $15K Worth of Stock Options
June 21, 2023 | benzinga.com
Impel Pharmaceuticals Director Awarded $15K Worth of Stock Options
June 15, 2023 | finance.yahoo.com
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
May 17, 2023 | uk.finance.yahoo.com
Impel Pharmaceuticals Inc. (IMPL)
May 13, 2023 | finance.yahoo.com
Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations
May 12, 2023 | msn.com
Recap: Impel Pharmaceuticals Q1 Earnings
May 12, 2023 | finance.yahoo.com
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 | msn.com
Earnings Outlook For Impel Pharmaceuticals
May 10, 2023 | msn.com
Impel Pharmaceuticals gets new CFO
May 10, 2023 | finance.yahoo.com
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/17/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
CUSIP
N/A
CIK
1445499
Web
www.Impelnp.com
Phone
206-568-1466
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%
Return on Equity
N/A
Return on Assets
-127.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.13

Sales & Book Value

Annual Sales
$20.99 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
23,900,000
Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Leonard S. Paolillo (Age 44)
    Interim President & CEO
    Comp: $523.97k
  • Dr. John D. Hoekman Ph.D. (Age 42)
    Co-Founder and Chief Technology & Development Officer
  • Mr. Michael W. Kalb CPA (Age 52)
    Chief Financial Officer
  • Ms. Jennifer L. Berman
    Vice President of Marketing
  • Ms. Sarah Wille
    Vice President of Human Resources
  • Dr. Lynn C. Gold Ph.D. (Age 66)
    Senior Vice President of Regulatory
  • Mr. Scott Youmans (Age 56)
    Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

IMPL Stock Analysis - Frequently Asked Questions

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.42. The company earned $0.09 million during the quarter.

When did Impel Pharmaceuticals IPO?

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

This page (NASDAQ:IMPL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Biden out June 13; Kamala won’t replace him?
Paradigm Press
The #1 Crypto for 2024
InvestorPlace